Next-generation drug-eluting stents in coronary artery disease: Focus on everolimus-eluting stent (Xience V®)

Vascular Health and Risk Management

Volumn 4, Issue 1, 2008, Pages 31-38

  Sheiban, Imad ^a   Villata, Gianluca ^b   Bollati, Mario ^a   Sillano, Dario ^a   Lotrionte, Marzia ^b   Biondi Zoccai, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Coronary artery disease; Everolimus; Percutaneous transluminal coronary angioplasty; Stent

Indexed keywords

ANTITHROMBOCYTIC AGENT; EVEROLIMUS; PACLITAXEL; POLYMER; RAPAMYCIN; ZOTAROLIMUS;

ADJUVANT THERAPY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; GRAFT REJECTION; HUMAN; NONHUMAN; PATIENT SAFETY; RESTENOSIS; REVIEW; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS;

EID: 41549119124     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2008.04.01.31     Document Type: Review

References (66)

1. Agostoni P, Sangiorgi GM, Biondi-Zoccai GG. 2007. Treatment of restenosis with a paclitaxel-coated balloon catheter. N Engl J Med, 356:1071-2; author reply 1072-3.
2. Agostoni P, Valgimigli M, Abbate A, et al. 2006. Is late luminal loss an accurate predictor of the clinical effectiveness of drug-eluting stents in the coronary arteries? Am J Cardiol, 97:603-5.
3. Airoldi F, Colombo A, Morici N, et al. 2007. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation, 116:745-54.
4. Albiero R, Adamian M, Kobayashi N, et al. 2000a. Short- and intermediate-term results of (32)P radioactive beta-emitting stent implantation in patients with coronary artery disease: The Milan Dose-Response Study. Circulation, 101:18-26.
5. Albiero R, Nishida T, Adamian M, et al. 2000b. Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. Circulation, 101:2454-7.
6. Beijk MA, Piek JJ. 2007. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Expert Rev Med Devices, 4:11-21.
7. Biondi-Zoccai GG, Abbate A, Agostoni P, et al. 2003. Stenting versus surgical bypass grafting for coronary artery disease: systematic overview and meta-analysis of randomized trials. Ital Heart J, 4:271-80.
8. Biondi-Zoccai GG, Abbate A, Agostoni P, et al. 2005a. Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression. Am Heart J, 149:504-11.
9. Biondi-Zoccai GG, Agostoni P, Abbate A, et al. 2005b. A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol, 34:224-5.
10. Biondi-Zoccai GG, Agostoni P, Abbate A, et al. 2005c. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials. Int J Cardiol, 100:119-23.
11. Biondi-Zoccai GG, Agostoni P, Sangiorgi GM, et al. 2006a. Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation. Eur Heart J, 27:540-6.
12. Biondi-Zoccai GG, Chieffo A, Agostoni P, et al. 2005d. Applying intravascular ultrasound to optimize the placement of coronary drug-elutings stents. Minerva Cardioangiol, 53:165-76.
13. Biondi-Zoccai GG, Lotrionte M, Abbate A, et al. 2007. Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus-versus paclitaxel-eluting stents across 5854 patients. Int J Cardiol, 114:104-5.
14. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. 2006b. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J, 27:2667-74.
15. Biondi-Zoccai GG, Testa L, Agostoni P. 2004. A practical algorithm for systematic reviews in cardiovascular medicine. Ital Heart J, 5:486-7.
16. Boden WE, O'Rourke RA, Teo KK, et al. 2007. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med, 356:1503-16.
17. Burzotta F, Trani C, Romagnoll E, et al. 2005. Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J Am Coll Cardiol, 46:371-6.
18. Carter AJ. 2004. TOR of the cell cycle: Are there important implications for diabetics in the era of the drug-eluting stent? Catheter Cardiovasc Interv, 61:233-6.
19. Carter AJ, Brodeur A, Collingwood R, et al. 2006. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter Cardiovasc Interv, 68:97-103.
20. Colombo A, Drzewiecki J, Banning A, et al. 2003. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation, 108:788-94.
21. Cosgrave J, Corbett SJ, Melzi G, et al. 2007. Late restenosis following sirolimus-eluting stent implantation. Am J Cardiol, 100:41-4.
22. Costa RA, Lansky AJ, Mintz GS, et al. 2005. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol, 95:113-6.
23. Eisen HJ, Tuzcu EM, Dorent R, et al. 2003. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med, 349:847-58.
24. Erne P, Schoenenberger AW, Burckhardt D, et al. 2007. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA, 297:1985-91.
25. Fajadet J, Wijns W, Laarman GJ, et al. 2006. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation, 114:798-806.
26. Fajadet J, Wijns W, Laarman GJ, et al. 2007. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphory1choline-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. Minerva Cardioangiol, 55:1-18.
27. Fischman DL, Leon MB, Baim DS, et al. 1994. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med, 331:496-501.
28. Grines CL, Bonow RO, Casey DE Jr, et al. 2007 Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation, 115:813-8.
29. Grube E, Buellesfeld L. 2004a. Everolimus for stent-based intracoronary applications. Rev Cardiovasc Med, 5(Suppl 2):S3-8.
30. Grube E, Buellesfeld L. 2004b. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents. Herz, 29:162-6.
31. Grube E, Lansky A, Hauptmann KE, et al. 2004a. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol, 44:1368-72.
32. Grube E, Silber S, Hauptmann KE, et al. 2003. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation, 107:38-42.
33. Grube E, Sonoda S, Ikeno F, et al. 2004b. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation, 109:2168-71.
34. Gruntzig A. 1978. Transluminal dilatation of coronary-artery stenosis. Lancet, 1:263.
35. Gruntzig AR, Serming A, Siegenthaler WE. 1979. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med, 301:61-8.
36. Hagemeister J, Baer FM, Schwinger RH, et al. 2005. Compliance of a cobalt chromium coronary stent alloy - the COVIS trial. Curr Control Trials Cardiovasc Med, 6:17.
37. Hiatt BL, Ikeno F, Yeung AC, et al. 2002. Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail. Catheter Cardiovasc Interv, 55:409-17.
38. Hill RA, Dundar Y, Bakhai A, et al. 2004. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J, 25:902-19.
39. Hochman JS, Lamas GA, Buller CE, et al. 2006. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med, 355:2395-407.
40. Hochman JS, Sleeper LA, White HD, et al. 2001. One-year survival following early revascularization for cardiogenic shock. JAMA, 285:190-2.
41. Iakovou I, Schmidt T, Bonizzoni E, et al. 2005. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 293:2126-30.
42. Kahan BD, Wong RL, Carter C, et al. 1999. A phase I study of a 4-week course of SDZ-RAD, (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation, 68:1100-6.
43. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. 2005. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet, 366:921-9.
44. Kandzari DE, Leon MB, Popma JJ, et al. 2006. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol, 48:2440-7.
45. Kasaoka S, Tobis JM, Akiyama T, et al. 1998. Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol, 32:1630-5.
46. Leon MB. 2007. Endeavor clinical trial program [online]. Accessed 16 October 2007. URL: http://www.crtonline.org/flash.aspx?PAGE_ID=4728.
47. Leon MB, Teirstein PS, Moses JW, et al. 2001. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med, 344:250-6.
48. Martinet W, Verheye S, De Meyer GR. 2007a. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy, 3:241-4.
49. Martinet W, Verheye S, De Meyer, GR. 2007b. Selective depletion of macrophages in atherosclerotic plaques via macrophage-specific initiation of cell death. Trends Cardiovasc Med, 17:69-75.
50. McFadden EP, Stabile E, Regar E, et al. 2004. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet, 364:1519-21.
51. Meredith I, Ormiston J, Whitbourn R, et al. 2005. First-in-human study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I trial. EuroIntervention, 1:157-64.
52. Morice MC, Serruys PW, Sousa JE, et al. 2002. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med, 346:1773-80.
53. Moses JW, Leon MB, Popma JJ, et al. 2003. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 349:1315-23.
54. Ortolani P, Marzocchi A, Marrozzini C, et al. 2007. Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheter Cardiovasc Interv, 69:790-8.
55. Serruys P, Ong A, Piek JJ, et al. 2005. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention, 1:58-65.
56. Serruys P, Ruygrok P, Neuzner J, et al. 2006. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention, 2:286-94.
57. Serruys PW, De Jaegere P, Kiemeneij F, et al. 1994. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med, 331:489-95.
58. Stone GW, Ellis SG, Cox DA, et al. 2004. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med, 350:221-31.
59. Tanimoto S, Serruys PW, Thuesen L, et al. 2007. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv, 70:515-23.
60. Tsuchida K, Garcia-Garcia HM, Ong AT, et al. 2006. Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. Catheter Cardiovasc Interv, 67:188-97.
61. Tsuchiya, Y., Lansky, A. J., Costa, R. A., et al. (2006) Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol, 98, 464-9.
62. Verheye S, Martinet W, Kockx MM, et al. 2007. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol, 49:706-15.
63. Versaci F, Gaspardone A, Tomai F, et al. 2002. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol, 40:1935-42.
64. Waksman R, Ajani AE, White RL, et al. 2002. Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med, 346:1194-9.
65. Waksman R, Pakala R, Baffour R, et al. 2006. Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries. Cardiovasc Revasc Med, 7:179-84.
66. Xu YW, Wei YD, Tang K, et al. 2007. Multi-link Vision and MiniVision stent registry in Asian patients with coronary artery disease: a prospective, multi-center study. Chin Med J (Engl), 120:1093-6.